Myotonic Dystrophy Type 1 (DM1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults. DM1 is a dominant disorder characterized by multisystemic clinical features affecting skeletal muscle, heart, and the nervous and endocrine systems.

·       The prevalence varies by region and is most common in individuals of European descent. According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses combined prevalence reported as 1 in 8,000 (12.5 per 100,000).

·       Myotonic Dystrophy Type 1 (DM1) is caused by the expansion of a CTG repeat in the 3' noncoding region of the DMPK gene on chromosome 19q13.3, which codes for the myotonic dystrophy protein kinase.

·       Normal individuals have between 5 and 37 repeats, but symptomatic patients typically have > 50 repeats.

DM1 is categorized into four subtypes: congenital, childhood, classic, and minimal/late-onset.

Thelansis’s “Myotonic Dystrophy Type 1 (DM1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myotonic Dystrophy Type 1 (DM1) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Myotonic Dystrophy Type 1 (DM1) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Myotonic Dystrophy Type 1 (DM1) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Myotonic Dystrophy Type 1 (DM1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033